2. Search Result
Search Result
Results for "

hyperplasia

" in MedChemExpress (MCE) Product Catalog:

52

Inhibitors & Agonists

7

Peptides

2

Inhibitory Antibodies

6

Natural
Products

8

Isotope-Labeled Compounds

2

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-113405
    21-Deoxycortisol

    		Endogenous Metabolite Endocrinology
    21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia .
    21-Deoxycortisol
  • HY-113603
    Tildacerfont

    SPR001; LY2371712

    		 CRFR Cancer
    Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia .
    Tildacerfont
  • HY-P1442
    AdTx1

    		Adrenergic Receptor Cancer
    AdTx1 is a selective α1A-adrenoceptor antagonist (Ki: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia .
    AdTx1
  • HY-156522
    CRF1 receptor antagonist-1

    		CFTR Endocrinology
    CRF1 receptor antagonist-1 (Compound 2) is a CRF1 receptor antagonist. CRF1 receptor antagonist-1 can be used for research of congenital adrenal hyperplasia (CAH) .
    CRF1 receptor antagonist-1
  • HY-106203
    Crinecerfont

    SSR-125543

    		 CFTR Metabolic Disease
    Crinecerfont (SSR-125543) hydrochloride is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Crinecerfont
  • HY-106203A
    Crinecerfont hydrochloride

    SSR-125543 hydrochloride

    		 CFTR Metabolic Disease
    Crinecerfont (SSR-125543) hydrochloride is a potent, orally active, non-peptide CRF1 receptor antagonist. Crinecerfont can be used for Classic congenital adrenal hyperplasia (CAH) research . Crinecerfont (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Crinecerfont hydrochloride
  • HY-B0661
    Tamsulosin

    (R)-(-)-YM12617 free base; LY253351 free base

    		 Adrenergic Receptor Endogenous Metabolite Neurological Disease Endocrinology Cancer
    Tamsulosin ((R)-(-)-YM12617 free base) is an inhibitor of α1-adrenergic receptor. Tamsulosin is used for the research of prostatic hyperplasia. Tamsulosin attenuates abdominal aortic aneurysm growth in animal models .
    Tamsulosin
  • HY-B0391B
    Naftopidil hydrochloride

    KT-611 hydrochloride; BM-15275 hydrochloride

    		 Adrenergic Receptor Cancer
    Naftopidil hydrochloride (KT-611 hydrochloride) is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil hydrochloride has antiproliferative effects. Naftopidil hydrochloride can be used for the research of prostate hyperplasia .
    Naftopidil hydrochloride
  • HY-P3501
    Fexapotide

    NX-1207 free acid

    		 Apoptosis Cancer
    Fexapotide (NX-1207 free acid) induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .
    Fexapotide
  • HY-P3501A
    Fexapotide TFA

    NX-1207 TFA

    		 Apoptosis Cancer
    Fexapotide (NX-1207) TFA induces apoptosis selectively, reducing prostate volume at a cellular level. Fexapotide can be used in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) research .
    Fexapotide TFA
  • HY-B0391
    Naftopidil

    KT-611; BM-15275

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology
    Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia .
    Naftopidil
  • HY-B0391A
    Naftopidil dihydrochloride

    KT-611 dihydrochloride; BM-15275 dihydrochloride

    		 Adrenergic Receptor Cancer
    Naftopidil dihydrochloride (KT-611 dihydrochloride) is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil dihydrochloride has antiproliferative effects. Naftopidil dihydrochloride can be used for the research of prostate hyperplasia .
    Naftopidil dihydrochloride
  • HY-P3412
    MMI-0100

    		MAPKAPK2 (MK2) Inflammation/Immunology
    MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease .
    MMI-0100
  • HY-B0371
    Terazosin

    		Adrenergic Receptor Metabolic Disease Endocrinology
    Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin
  • HY-B0371F
    Terazosin hydrochloride
    4 Publications Verification

    		 Adrenergic Receptor Metabolic Disease Endocrinology
    Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin hydrochloride
  • HY-107637
    ONO-4817

    		MMP Cardiovascular Disease
    ONO-4817 is a potent inhibitor of matrix metalloproteinase (MMP). Inhibition of matrix metalloproteinases (MMPs) is expected to suppress atherosclerotic neointimal proliferation and thus limits atheromatous plaque progression. ONO-4817 suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit .
    ONO-4817
  • HY-B0371A
    Terazosin hydrochloride dihydrate
    4 Publications Verification

    		 Adrenergic Receptor Metabolic Disease Endocrinology
    Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment .
    Terazosin hydrochloride dihydrate
  • HY-107385
    Epristeride

    ONO-9302; SKF105657

    		 5 alpha Reductase Cancer
    Epristeride (ONO-9302) is a selective, specific and orally active uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2. Epristeride has inhibitory effects for SR isoenzymes types 2 with Ki value of 0.7-2 nM. Epristeride can be used for the research of prostatic hyperplasia and acne .
    Epristeride
  • HY-N8850
    Angelol G

    		Others Cancer
    Angelol G, a coumarin, can be isolated from Campylotropis hirtella. Angelol G shows inhibitory activity for prostate specific antigen (PSA)IC50 value of 152.1μM. Angelol G can be used for the research of benign prostate hyperplasia (BPH) .
    Angelol G
  • HY-13635
    Finasteride
    4 Publications Verification

    MK-906

    		 5 alpha Reductase Cancer
    Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
    Finasteride
  • HY-13635A
    Finasteride acetate

    MK-906 acetate

    		 5 alpha Reductase Cancer
    Finasteride (MK-906) acetate is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride acetate has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride acetate can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
    Finasteride acetate
  • HY-103204
    RS100329 hydrochloride

    		Adrenergic Receptor Endocrinology
    RS100329 hydrochloride is a potent and selective α1A-adrenoceptor antagonist with pKi values of 9.6, 7.9 and 7.5 for α1A, α1D, and α1B, respectively. RS100329 hydrochloride inhibits reflex urethral contractions. RS100329 hydrochloride can be used in research of benign prostatic hyperplasia .
    RS100329 hydrochloride
  • HY-113405S1
    21-Deoxycortisol-d8

    		Isotope-Labeled Compounds Endogenous Metabolite Endocrinology
    21-Deoxycortisol-d8 is the deuterium labeled 21-Deoxycortisol. 21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia[1].
    21-Deoxycortisol-d8
  • HY-115450
    ONO-0300302

    		LPL Receptor Endocrinology Cancer
    ONO-0300302 is an orally active and potent LPA1 (lysophosphatidic acid receptor 1) antagonist, with an IC50 of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with Kd of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research .
    ONO-0300302
  • HY-B0192AS1
    Alfuzosin-d7 hydrochloride

    SL 77499-10-d7

    		 Adrenergic Receptor Endocrinology
    Alfuzosin-d7 (hydrochloride) is the deuterium labeled Alfuzosin hydrochloride. Alfuzosin hydrochloride is an α1 adrenergic receptor antagonist used to treat benign prostatic hyperplasia (BPH).
    Alfuzosin-d7 hydrochloride
  • HY-B0391S1
    Naftopidil-d5

    KT-611-d5; BM-15275-d5

    		 Isotope-Labeled Compounds Adrenergic Receptor Cardiovascular Disease Endocrinology
    Naftopidil-d5 is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].
    Naftopidil-d5
  • HY-P2563
    [Tyr(P)4] Angiotensin II

    		Angiotensin Receptor Metabolic Disease
    [Tyr(P)4] Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels .
    [Tyr(P)4] Angiotensin II
  • HY-P1564
    [Sar1, Ile8]-Angiotensin II

    		Angiotensin Receptor Cardiovascular Disease Endocrinology
    [Sar1, Ile8]-Angiotensin II is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.
    [Sar1, Ile8]-Angiotensin II
  • HY-P1564A
    [Sar1, Ile8]-Angiotensin II TFA

    AngiotensinII TFA; Angiotensin 2 TFA

    		 Angiotensin Receptor Others
    [Sar1, Ile8]-Angiotensin II (TFA) is a peptide that has multiple effects on vascular smooth muscle, including contraction of normal arteries and hypertrophy or hyperplasia of cultured cells or diseased vessels.
    [Sar1, Ile8]-Angiotensin II TFA
  • HY-105173
    Teverelix

    EP 24332

    		 GnRH Receptor Histamine Receptor Endocrinology Cancer
    Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer .
    Teverelix
  • HY-N8856
    Angelol M

    		Others Others
    Angelol M,isolated from the roots of Angelica gigas Nakai, shows activity in inhibiting prostate specific antigen (PSA) secreted from androgen dependent prostate cancer cell line, LNCaP cells .
    Angelol M
  • HY-B0661A
    Tamsulosin hydrochloride

    (R)-(-)-YM12617; LY253351

    		 Adrenergic Receptor Endogenous Metabolite Neurological Disease Endocrinology Cancer
    Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models .
    Tamsulosin hydrochloride
  • HY-B0192A
    Alfuzosin hydrochloride
    1 Publications Verification

    SL 77499-10

    		 Adrenergic Receptor Endocrinology
    Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin hydrochloride
  • HY-B0192
    Alfuzosin

    SL 77499

    		 Adrenergic Receptor Endocrinology
    Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) .
    Alfuzosin
  • HY-147152
    1-Myristoyl-3-chloropropanediol

    		Others Others
    1-Myristoyl-3-chloropropanediol is a 3-monochloropropanediol (3-MCPD) fatty acid ester. 3-MPCD causes nephropathy and tubular hyperplasia and adenomas by chronic oral administration; also reduces fertility, or provokes infertility in rats and suppresses the immune function .
    1-Myristoyl-3-chloropropanediol
  • HY-19702
    PKR activator 3

    		Pyruvate Kinase Metabolic Disease Inflammation/Immunology Cancer
    PKR activator 3 is a pyruvate kinase isoform PKR activator extracted from patent WO2014139144A1, compound 160. PKR activator 3 can be used for the research of PKR function related diseases, including cancer, diabetes, obesity, autoimmune disorders, and benign prostatic hyperplasia .
    PKR activator 3
  • HY-B0661AS
    Tamsulosin-d5 hydrochloride

    		Isotope-Labeled Compounds Adrenergic Receptor Endogenous Metabolite Neurological Disease Endocrinology
    Tamsulosin-d5 (hydrochloride) is the deuterium labeled Tamsulosin hydrochloride. Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models[1].
    Tamsulosin-d5 hydrochloride
  • HY-B0661AS1
    Tamsulosin-d4 hydrochloride

    (R)-(-)-YM12617-d4; LY253351-d4

    		 Isotope-Labeled Compounds Adrenergic Receptor Endogenous Metabolite Neurological Disease Endocrinology
    Tamsulosin-d4 (hydrochloride) is deuterium labeled Tamsulosin (hydrochloride). Tamsulosin hydrochloride ((R)-(-)-YM12617) is an inhibitor of α1-adrenergic receptor. Tamsulosin hydrochloride is used for the research of prostatic hyperplasia. Tamsulosin hydrochloride attenuates abdominal aortic aneurysm growth in animal models[1].
    Tamsulosin-d4 hydrochloride
  • HY-B0371S
    Terazosin-d8

    		Isotope-Labeled Compounds Adrenergic Receptor Metabolic Disease Endocrinology
    Terazosin-d8 is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].
    Terazosin-d8
  • HY-B0192S
    Alfuzosin-d7

    SL 77499-d7

    		 Adrenergic Receptor Endocrinology
    Alfuzosin-d7 is the deuterium labeled Alfuzosin[1]. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[2][3].
    Alfuzosin-d7
  • HY-P99588
    Stamulumab

    MYO-029

    		 TGF-β Receptor Metabolic Disease
    Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .
    Stamulumab
  • HY-103459
    CI-1020

    PD156707

    		 Endothelin Receptor Cardiovascular Disease
    CI-1020 (PD156707) is an orally active and selective antagonist targeting endothelin (ETA) with an IC50 value of 0.3 nM. CI-1020 blocks intimal hyperplasia in human saphenous veins completely in organ culture. CI 1020 inhibits hypoxic pulmonary hypertension and blocks ET-1-induced pressor responses following oral administration .
    CI-1020
  • HY-13810
    PF-04880594

    		Raf Cancer
    PF-04880594 is a potent and selective RAF inhibitor. PF-04880594 inhibits both wild-type and mutant BRAF and CRAF. PF-04880594 shows antitumor activity .
    PF-04880594
  • HY-13635S
    Finasteride-d9

    MK-906-d9

    		 Isotope-Labeled Compounds 5 alpha Reductase Cancer
    Finasteride-d9 is deuterium labeled Finasteride. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia[1][2][3].
    Finasteride-d9
  • HY-13635R
    Finasteride (Standard)

    MK-906 (Standard)

    		 5 alpha Reductase Cancer
    Finasteride (Standard) is the analytical standard of Finasteride. This product is intended for research and analytical applications. Finasteride (MK-906) is a potent and competitive 5α-reductase inhibitor, with an IC50 of 4.2 nM for type II 5α-reductase. Finasteride has approximately a 100-fold greater affinity for type II 5α-reductase enzyme than for the type I enzyme. Finasteride can be used for the research of benign prostatic hyperplasia (BPH) and androgenic alopecia .
    Finasteride (Standard)
  • HY-163176
    WB518

    		STAT Inflammation/Immunology
    WB518 is a potent STAT3 inhibitor. WB518 effectively inhibits STAT3 activation and Keratin 17 expression. WB518 effectively alleviates imiquimod (HY-B0180) and TPA (HY-18739)-induced animal psoriasis by inhibiting STAT3 phosphorylation and Keratin 17 .
    WB518
  • HY-130622
    LT052

    		Epigenetic Reader Domain Inflammation/Immunology
    LT052 is a highly selective BET BD1 inhibitor with an IC50 of 87.7 nM. LT052 exhibits nanomolar BRD4 BD1 potency and 138-fold selectivity over BRD4 BD2 (IC50=12.130 μM). LT052 has anti-inflammatory activity and can be used for acute gout arthritis research .
    LT052
  • HY-135473
    Chlormadinone

    		Others Others
    Chlormadinone is an antiandrogen drug. Chlormadinone combined with Tamsulosin shows greater improvement in subjective symptoms of BPH .
    Chlormadinone
  • HY-10122
    Silodosin
    2 Publications Verification

    KAD 3213; KMD 3213

    		 Adrenergic Receptor Bacterial Endocrinology Cancer
    Silodosin (KAD 3213; KMD 3213) is a potent, selective and orally active α1A-adrenergic receptor (α1A-AR) blocker. Silodosin exhibits high affinity for α1A-AR (Ki=0.036 nM), over 162-fold and 50-fold than for α1B-AR and α1D-AR with Ki values of 21 nM and 2.0 nM, respectively. Silodosin is an effective and well-tolerated agent, it can be used for the investigation of LUTS/BPH .
    Silodosin
  • HY-P9934
    Abciximab

    C7E3

    		 Integrin Cardiovascular Disease
    Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors .
    Abciximab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: